{"id":"mfolfirinox-regimen","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This is a combination chemotherapy regimen where each agent targets cancer cell proliferation through different mechanisms: 5-FU and leucovorin inhibit thymidylate synthase, irinotecan inhibits topoisomerase I, and oxaliplatin causes DNA cross-linking. The 'modified' (mFOLFIRINOX) version typically refers to adjusted dosing schedules designed to improve tolerability while maintaining efficacy compared to the standard regimen.","oneSentence":"mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:14.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Metastatic colorectal cancer"},{"name":"Gastric cancer"},{"name":"Biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT07477418","phase":"PHASE1, PHASE2","title":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT06850623","phase":"PHASE2","title":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"EXACT Therapeutics AS","startDate":"2025-06-19","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":25},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT07026279","phase":"PHASE1, PHASE2","title":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Amplia Therapeutics Limited","startDate":"2025-08-18","conditions":"Pancreatic Cancer Metastatic","enrollment":67},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":13},{"nctId":"NCT07166601","phase":"PHASE1","title":"M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-10-10","conditions":"Advanced Solid Tumor","enrollment":77},{"nctId":"NCT07407231","phase":"NA","title":"Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-09-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":18},{"nctId":"NCT07044453","phase":"PHASE2, PHASE3","title":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-12-08","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":390},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT03983057","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":392},{"nctId":"NCT07326137","phase":"","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-26","conditions":"Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain","enrollment":103},{"nctId":"NCT07214298","phase":"PHASE1, PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07255404","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-04","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":105},{"nctId":"NCT04161755","phase":"PHASE1","title":"Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT03991962","phase":"PHASE2","title":"Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2019-09-24","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT04888312","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alligator Bioscience AB","startDate":"2021-09-17","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":94},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT06831136","phase":"PHASE2","title":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-03-26","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":24},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT05585320","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immuneering Corporation","startDate":"2022-10-31","conditions":"Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)","enrollment":209},{"nctId":"NCT06249321","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Radiotherapy","enrollment":30},{"nctId":"NCT06149689","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-10","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06966440","phase":"NA","title":"Adjuvant Pancreatic Therapy Guided by MRD","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Pancreatic Adenocarcinoma Resectable","enrollment":856},{"nctId":"NCT06813976","phase":"PHASE3","title":"PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-07-02","conditions":"Ampullary Adenocarcinoma","enrollment":294},{"nctId":"NCT07034703","phase":"","title":"Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-09","conditions":"Resectable Pancreatic Duct Adenocarcinoma","enrollment":820},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT04292743","phase":"PHASE1","title":"Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2020-12-02","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT04990609","phase":"PHASE2","title":"EUS-RFA PANCARDINAL-1 Trial","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-08-13","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":60},{"nctId":"NCT03750669","phase":"PHASE3","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-20","conditions":"Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy","enrollment":324},{"nctId":"NCT03374852","phase":"PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-08","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":""},{"nctId":"NCT06944587","phase":"","title":"A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-12-03","conditions":"Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy","enrollment":400},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT06913218","phase":"PHASE1","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-07-22","conditions":"Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma","enrollment":60},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT06888648","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-01","conditions":"Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable","enrollment":30},{"nctId":"NCT06757244","phase":"PHASE2","title":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2025-02-18","conditions":"Pancreas Neoplasms","enrollment":35},{"nctId":"NCT06867146","phase":"NA","title":"MRD in PAAD Adjuvant Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-10-15","conditions":"The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer","enrollment":60},{"nctId":"NCT06844422","phase":"PHASE1, PHASE2","title":"Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-08","conditions":"Pancreatic Cancer","enrollment":37},{"nctId":"NCT05257993","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-03-30","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT03899636","phase":"PHASE3","title":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angiodynamics, Inc.","startDate":"2021-02-23","conditions":"Stage III Pancreatic Cancer","enrollment":528},{"nctId":"NCT06538207","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Metastatic Pancreatic Cancer","enrollment":46},{"nctId":"NCT02672917","phase":"PHASE1","title":"Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies","status":"TERMINATED","sponsor":"BioNTech Research & Development, Inc.","startDate":"2016-01","conditions":"Pancreatic Cancer","enrollment":118},{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT06761027","phase":"PHASE1, PHASE2","title":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-12-23","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":29},{"nctId":"NCT04807972","phase":"PHASE1","title":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-05-28","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT06532344","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-07-30","conditions":"Metastatic Pancreatic Cancer","enrollment":32},{"nctId":"NCT06389760","phase":"PHASE2","title":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10-18","conditions":"Pancreatic Cancer","enrollment":57},{"nctId":"NCT06518538","phase":"PHASE2","title":"Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2024-08-15","conditions":"Pancreatic Cancer Stage IV","enrollment":""},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT04672005","phase":"PHASE2","title":"Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lyudmyla Berim","startDate":"2021-01-06","conditions":"Metastatic Pancreatic Cancer","enrollment":30},{"nctId":"NCT06353581","phase":"PHASE2","title":"Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2022-02-16","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":78},{"nctId":"NCT06278545","phase":"PHASE2","title":"Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-02-16","conditions":"Locally Advanced or Metastatic Small Bowel Adenocarcinoma","enrollment":130},{"nctId":"NCT06151262","phase":"PHASE2","title":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-01-20","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01959139","phase":"PHASE1, PHASE2","title":"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-01-23","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":126},{"nctId":"NCT06156267","phase":"EARLY_PHASE1","title":"Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT02231723","phase":"PHASE1","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-08","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":139},{"nctId":"NCT06068023","phase":"","title":"The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.","status":"RECRUITING","sponsor":"Fondazione Poliambulanza Istituto Ospedaliero","startDate":"2023-07-01","conditions":"Ampullary Adenocarcinoma","enrollment":400},{"nctId":"NCT05070104","phase":"PHASE1","title":"CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2023-03-30","conditions":"C04.588.274.476.411.307","enrollment":""},{"nctId":"NCT05926206","phase":"PHASE1, PHASE2","title":"Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2023-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT05959395","phase":"NA","title":"Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors","status":"UNKNOWN","sponsor":"NeoTherma Oncology","startDate":"2023-08-15","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT04990037","phase":"PHASE1","title":"A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-07-19","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT05083247","phase":"PHASE2","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Erasme University Hospital","startDate":"2023-03-24","conditions":"Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":256},{"nctId":"NCT03977272","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-03-27","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT03504423","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2018-11-09","conditions":"Pancreatic Cancer Metastatic","enrollment":528},{"nctId":"NCT05665023","phase":"PHASE2","title":"Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-10-28","conditions":"Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":37},{"nctId":"NCT01926197","phase":"PHASE3","title":"Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-14","conditions":"Pancreatic Cancer","enrollment":27},{"nctId":"NCT03099265","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-26","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT02591030","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-15","conditions":"Bile Duct Cancer","enrollment":191},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT04089150","phase":"PHASE2","title":"MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2019-10-01","conditions":"Pancreatic Cancer","enrollment":120},{"nctId":"NCT05066802","phase":"PHASE2","title":"A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-11","conditions":"Resectable Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT01676259","phase":"PHASE2","title":"A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Silenseed Ltd","startDate":"2018-03-07","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer","enrollment":80},{"nctId":"NCT04835064","phase":"PHASE3","title":"Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-01","conditions":"Pancreatic Adenocarcinoma","enrollment":600},{"nctId":"NCT03778593","phase":"PHASE2","title":"FOLFIRINOX for 2nd-line Treatment of BTC","status":"COMPLETED","sponsor":"Dong-A University Hospital","startDate":"2019-03-01","conditions":"Biliary Tract Cancer","enrollment":34},{"nctId":"NCT04305288","phase":"","title":"Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-01-01","conditions":"Cholangiocarcinoma of the Bile Duct","enrollment":100},{"nctId":"NCT03042780","phase":"PHASE2","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-02-01","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["modified FOLFIRINOX regimen","modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU)","Folic acid, 5- fluorouracil, irinotecan and oxaliplatin","Oxaliplatin","Irinotecan"],"phase":"phase_3","status":"active","brandName":"mFOLFIRINOX regimen","genericName":"mFOLFIRINOX regimen","companyName":"Revolution Medicines, Inc.","companyId":"revolution-medicines-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic pancreatic cancer, Metastatic colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}